Livanova PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Feb 2026

LIVN

10-K: LivaNova Reports $242M Net Loss in 2025 Amidst SNIA Liability

LivaNova PLC reported a significant net loss of $242.5 million for 2025, primarily driven by a substantial SNIA environmental liability, despite strong revenue growth in its core Cardiopulmonary and Neuromodulation segments.

NASDAQ

25 Feb 2025

LIVN

Livanova PLC

10-K: LivaNova PLC Reports Strong Consumables Demand and Strategic Restructuring in 2024

LivaNova PLC's 2024 10-K filing reveals a year of strategic restructuring, revenue growth in Cardiopulmonary and Neuromodulation segments, and ongoing management of cybersecurity incidents and legal proceedings.

NASDAQ

29 Feb 2024

LIVN

Livanova PLC

10-K: LivaNova PLC Details Share Structure and Regulatory Compliance in 10-K Filing

LivaNova PLC's 10-K filing outlines the company's share structure, dividend policies, voting rights, and compliance with UK and US regulations.